Antimony cation (5+)
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Antimony cation (5+)
- Molecular weight
- 121.76
- Structure (SMILES)
These details could not be displayed.
- Antimony cation (5+)
- antimony cation 5
- antimony ion sb5
- ANTIMONY, ION (SB5+)
- pentavalent antimony
- Pentavalent antimony
- Pentavalent antimony (Sbv)
- sb5
- SB5+
- CAS registry numbers
- 22537-51-5
- ChEMBL ID
- CHEMBL4297415
- InChIKey
- ZDINGUUTWDGGFF-UHFFFAOYSA-N
- PubChem compound IDs
- 73608879
- RxNorm IDs (RxCUI)
- 1546283
- FDA ingredient codes (UNII)
- 841L03HG64
- First in class
- No
- Orphan designation
- No
- Condition
- Leishmaniasis, Cutaneous
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005046
- Subject identifier
- D016773
- Condition
- Leishmaniasis, Mucocutaneous
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007379
- Subject identifier
- D007897
- Condition identifier
- EFO_0007379
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005446
- Highest recorded phase
- 2
- Event
- abdominal pain
- Reports
- 4
- Reporting signal score
- 10.3045
- Event
- disease progression
- Reports
- 3
- Reporting signal score
- 9.06575
- Event
- herpes zoster
- Reports
- 3
- Reporting signal score
- 10.4743
- Event
- hypergammaglobulinaemia
- Reports
- 3
- Reporting signal score
- 24.0826
- Event
- leishmaniasis
- Reports
- 3
- Reporting signal score
- 25.6057
- Event
- leukopenia
- Reports
- 3
- Reporting signal score
- 10.1625
- Event
- mastication disorder
- Reports
- 3
- Reporting signal score
- 20.1144
- Event
- mucocutaneous leishmaniasis
- Reports
- 3
- Reporting signal score
- 28.3544
- Event
- myalgia
- Reports
- 5
- Reporting signal score
- 16.1485
- Event
- nephropathy toxic
- Reports
- 2
- Reporting signal score
- 8.835
- Event
- ototoxicity
- Reports
- 3
- Reporting signal score
- 19.72
- Event
- palatal swelling
- Reports
- 3
- Reporting signal score
- 27.6392
- Event
- skin exfoliation
- Reports
- 2
- Reporting signal score
- 7.1741
- Event
- splenomegaly
- Reports
- 3
- Reporting signal score
- 15.2803
- Event
- tinnitus
- Reports
- 2
- Reporting signal score
- 7.29926
- Event
- visceral leishmaniasis
- Reports
- 6
- Reporting signal score
- 51.7211
- NCT01300975
- NCT04799236
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 1
- Molecular formula
- Sb+5
- Monoisotopic mass
- 120.90381
- Natural product
- Yes
- Recorded assays
- 2
- Active assays
- 0
Related records
Trials (63)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
- A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
- A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test
- A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
- A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.
- A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
- A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
- A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
- Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.
- BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women
- CART-38 in Adult AML and MM Patients
- CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers
- Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
- Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies
- Effect of Postoperative Ketorolac on Bone Healing After Joint Fusion
- Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
- Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
- Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
In development for (2)
- Cutaneous leishmaniasis Phase 2
- Mucocutaneous leishmaniasis Phase 3